Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 300INDUSTRY 9OTHER_GOV 2NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

Specimen Handling 354Magnetic Resonance Spectroscopy 253Biopsy 222Nivolumab 69Cyclophosphamide 66Carboplatin 56Radiation 53Paclitaxel 53Taxes 52Immunoglobulin G 52Disulfides 52pembrolizumab 51X-Rays 51Cisplatin 49Platinum 451,2-diaminocyclohexaneplatinum II citrate 45Doxorubicin 44Radiotherapy 42Ipilimumab 38atezolizumab 37fludarabine 36Gemcitabine 35CTLA-4 Antigen 35olaparib 32Vincristine 31Prednisone 31Bevacizumab 31venetoclax 27Cytarabine 27Rituximab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Blood Specimen Collection × 1 year × Clear all
NCT02453620 2026-04-13

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
57 enrolled
BreastOther solid neoplasm

Anatomic Stage III Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡